EA200970500A1 - СОЕДИНЕНИЯ ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛА В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРА АНДРОГЕНОВ - Google Patents

СОЕДИНЕНИЯ ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛА В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРА АНДРОГЕНОВ

Info

Publication number
EA200970500A1
EA200970500A1 EA200970500A EA200970500A EA200970500A1 EA 200970500 A1 EA200970500 A1 EA 200970500A1 EA 200970500 A EA200970500 A EA 200970500A EA 200970500 A EA200970500 A EA 200970500A EA 200970500 A1 EA200970500 A1 EA 200970500A1
Authority
EA
Eurasian Patent Office
Prior art keywords
tetrahydrocyclopent
androgen receptor
receptor modulators
compound
formula
Prior art date
Application number
EA200970500A
Other languages
English (en)
Other versions
EA015627B1 (ru
Inventor
Константинос Гавардинас
Джонатан Эдвард Грин
Прабхакар Кондаджи Джадхав
Дональд Пол Мэттьюз
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA200970500A1 publication Critical patent/EA200970500A1/ru
Publication of EA015627B1 publication Critical patent/EA015627B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/70—[b]- or [c]-condensed containing carbocyclic rings other than six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Настоящее изобретение обеспечивает соединение формулы (I) или его фармацевтически приемлемую соль; фармацевтические композиции, включающие соединение формулы (I) в комбинации с приемлемыми носителем, разбавителем или эксципиентом; и способ лечения физиологических заболеваний, в частности снижение костной массы, остеопороза, остеопении или снижение мышечной массы или силы, включающий введение соединения формулы (I) или его фармацевтически приемлемой соли.
EA200970500A 2006-11-20 2007-11-06 СОЕДИНЕНИЯ ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛА В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРА АНДРОГЕНОВ EA015627B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86648406P 2006-11-20 2006-11-20
PCT/US2007/083745 WO2008063867A2 (en) 2006-11-20 2007-11-06 Tetrahydrocyclopenta[b] indole compounds as androgen receptor modulators

Publications (2)

Publication Number Publication Date
EA200970500A1 true EA200970500A1 (ru) 2009-10-30
EA015627B1 EA015627B1 (ru) 2011-10-31

Family

ID=39415431

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200970500A EA015627B1 (ru) 2006-11-20 2007-11-06 СОЕДИНЕНИЯ ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛА В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРА АНДРОГЕНОВ

Country Status (37)

Country Link
US (1) US7968587B2 (ru)
EP (1) EP2094658B1 (ru)
JP (1) JP5399259B2 (ru)
KR (1) KR101121471B1 (ru)
CN (1) CN101541749B (ru)
AR (1) AR063559A1 (ru)
AT (1) ATE538091T1 (ru)
AU (1) AU2007324046B2 (ru)
BR (1) BRPI0719092B8 (ru)
CA (1) CA2670340C (ru)
CL (1) CL2007003182A1 (ru)
CO (1) CO6190513A2 (ru)
CR (1) CR10802A (ru)
CY (1) CY1112284T1 (ru)
DK (1) DK2094658T3 (ru)
EA (1) EA015627B1 (ru)
EC (1) ECSP099350A (ru)
ES (1) ES2376048T3 (ru)
HK (1) HK1134089A1 (ru)
HR (1) HRP20120032T1 (ru)
IL (1) IL198410A (ru)
JO (1) JO2800B1 (ru)
MA (1) MA31072B1 (ru)
MX (1) MX2009005251A (ru)
MY (1) MY154547A (ru)
NO (1) NO342531B1 (ru)
NZ (1) NZ576296A (ru)
PE (1) PE20081161A1 (ru)
PL (1) PL2094658T3 (ru)
PT (1) PT2094658E (ru)
RS (1) RS52191B (ru)
SI (1) SI2094658T1 (ru)
TN (1) TN2009000189A1 (ru)
TW (1) TWI398438B (ru)
UA (1) UA98777C2 (ru)
WO (1) WO2008063867A2 (ru)
ZA (1) ZA200903096B (ru)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009215843B2 (en) 2008-02-22 2011-09-08 Ellipses Pharma Ltd Selective androgen receptor modulators
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
CN102026974B (zh) * 2008-05-16 2013-08-28 伊莱利利公司 四氢环戊二烯并[b]吲哚雄激素受体调节剂
AR078862A1 (es) 2009-11-13 2011-12-07 Lilly Co Eli Ester isopropilico del acido ((s)-7-ciano-4-((2r,3s)-3-hidroxitetrahidrofuran-2-ilmetil)-1,2,3,4-tetrahidro-ciclopenta(b)indol-2-il)carbamico, composiciones farmaceuticas que lo comprenden y su uso en terapia
AU2011212813B2 (en) 2010-02-04 2014-10-23 Radius Health, Inc. Selective androgen receptor modulators
ME02474B (me) 2010-05-12 2017-02-20 Radius Health Inc Terapijski režimi
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
US9133182B2 (en) 2010-09-28 2015-09-15 Radius Health, Inc. Selective androgen receptor modulators
BR112013028895A2 (pt) 2011-05-10 2016-08-09 Bayer Ip Gmbh (tio)carbonilamidinas bicíclicas
CN103265479B (zh) * 2013-06-14 2017-12-08 南开大学 一种6‑氯甲基烟酸叔丁酯的合成方法
ES2939940T3 (es) 2014-03-28 2023-04-28 Univ Duke Tratamiento del cáncer de mama utilizando moduladores selectivos de los receptores de estrógenos
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
TWI677489B (zh) 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
JOP20180072A1 (ar) 2014-09-11 2019-01-30 Lilly Co Eli علاج الأعراض المرتبطة بالعلاج بالحرمان من الأندروجين
JP7221699B2 (ja) 2016-06-22 2023-02-14 エリプセス ファーマ エルティーディー Ａｒ＋乳癌の治療方法
US20180185347A1 (en) 2016-11-16 2018-07-05 Transition Therapeutics (Ireland 2) Limited Tetrahydrocyclopenta[b]indole compounds and phosphodiesterase inhibitors for the treatment of the signs and symptoms of bhp
FI3565542T3 (fi) 2017-01-05 2024-06-24 Radius Pharmaceuticals Inc Rad1901-2hcl:n polymorfisia muotoja
US11643385B2 (en) 2018-07-04 2023-05-09 Radius Pharmaceuticals, Inc. Polymorphic forms of RAD1901-2HCl
WO2021151905A1 (en) * 2020-01-27 2021-08-05 Transition Therapeutics (Ireland 2) Limited Tetrahydrocyclopenta[b]indole compounds for the treatment of renal disease
US11986461B1 (en) * 2023-08-24 2024-05-21 King Faisal University 3-(1-(3-(dimethylamino)propyl)-4,5-diphenyl-1H-imidazol-2-yl)pyridin-2-ol as an antitumor and antimicrobial compound

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4988820A (en) 1986-02-21 1991-01-29 Bayer Aktiengesellschaft Cycloalkano(1,2-B) indole-sulponamides
GB8924392D0 (en) 1989-10-30 1989-12-20 Bayer Ag Substituted cycloalkano/b/dihydroindole-and-indolesulphonamides
GB9008108D0 (en) 1990-04-10 1990-06-06 Bayer Ag Cycloalkano(b)dihydroindoles and-indolesulphonamides substituted by heterocycles
DE4027278A1 (de) 1990-08-29 1992-03-05 Bayer Ag Heterocyclisch substituierte indolsulfonamide
DE4131346A1 (de) 1991-09-20 1993-03-25 Bayer Ag Indolsulfonamid substituierte dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
AU7558900A (en) * 1999-10-14 2001-04-23 Kaken Pharmaceutical Co., Ltd. Tetrahydroquinoline derivatives
JP2005527464A (ja) 2001-08-09 2005-09-15 イーライ・リリー・アンド・カンパニー ｓＰＬＡ２インヒビターとしてのシクロヘプタＢインドール誘導体
DE10164564B4 (de) 2001-12-14 2007-05-16 Zentaris Gmbh Tetrahydrocarbazolderivate als Liganden für G-Protein gekoppelte Rezeptoren (GPCR)
AU2003231509A1 (en) 2002-05-16 2003-12-02 Shionogi And Co., Ltd. Compound exhibiting pgd 2 receptor antagonism
US20060074124A1 (en) 2003-09-12 2006-04-06 Andrew Napper Methods of treating a disorder
US20050245540A1 (en) * 2003-12-09 2005-11-03 Fujisawa Pharmaceutical Co., Ltd. New methods
US7019022B2 (en) 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
CA2557745A1 (en) * 2004-03-03 2005-10-06 Eli Lilly And Company Bicyclic substituted indole-derivative steroid hormone nuclear receptor modulators
US20090170923A1 (en) * 2004-11-22 2009-07-02 Kristjan Gudmundsson Hcv inhibitors
US8143257B2 (en) 2004-11-23 2012-03-27 Ptc Therapeutics, Inc. Substituted phenols as active agents inhibiting VEGF production
WO2006089053A2 (en) 2005-02-17 2006-08-24 Wyeth Cycloalkylfused indole, benzothiophene, benzofuran and indene derivatives
CN101203491A (zh) 2005-06-24 2008-06-18 伊莱利利公司 可用作雄激素受体调节剂的四氢咔唑衍生物（sarm）
US20090022694A1 (en) 2005-10-18 2009-01-22 Distefano Peter Sirt1 inhibition
WO2008019825A1 (en) 2006-08-14 2008-02-21 Santhera Pharmaceuticals (Schweiz) Ag Use of tricyclic indole derivatives for the treatment of muscular diseases
CN102026974B (zh) 2008-05-16 2013-08-28 伊莱利利公司 四氢环戊二烯并[b]吲哚雄激素受体调节剂

Also Published As

Publication number Publication date
IL198410A (en) 2013-09-30
KR101121471B1 (ko) 2012-02-28
CR10802A (es) 2009-07-13
CY1112284T1 (el) 2015-12-09
TN2009000189A1 (en) 2010-10-18
CO6190513A2 (es) 2010-08-19
CL2007003182A1 (es) 2008-06-27
EA015627B1 (ru) 2011-10-31
SI2094658T1 (sl) 2012-04-30
HRP20120032T1 (hr) 2012-02-29
AR063559A1 (es) 2009-02-04
MA31072B1 (fr) 2010-01-04
ZA200903096B (en) 2010-07-28
HK1134089A1 (en) 2010-04-16
NO342531B1 (no) 2018-06-11
TWI398438B (zh) 2013-06-11
EP2094658A2 (en) 2009-09-02
CA2670340A1 (en) 2008-05-29
CN101541749A (zh) 2009-09-23
JP2010510231A (ja) 2010-04-02
BRPI0719092B1 (pt) 2020-08-18
UA98777C2 (en) 2012-06-25
AU2007324046A1 (en) 2008-05-29
US20100069404A1 (en) 2010-03-18
IL198410A0 (en) 2010-02-17
US7968587B2 (en) 2011-06-28
JP5399259B2 (ja) 2014-01-29
WO2008063867A2 (en) 2008-05-29
BRPI0719092B8 (pt) 2021-05-25
ATE538091T1 (de) 2012-01-15
AU2007324046B2 (en) 2012-04-05
PT2094658E (pt) 2012-02-22
NO20092103L (no) 2009-05-28
DK2094658T3 (da) 2012-02-13
ES2376048T3 (es) 2012-03-08
RS52191B (en) 2012-10-31
ECSP099350A (es) 2009-06-30
EP2094658B1 (en) 2011-12-21
TW200827347A (en) 2008-07-01
PE20081161A1 (es) 2008-08-15
NZ576296A (en) 2011-11-25
JO2800B1 (en) 2014-03-15
KR20090082229A (ko) 2009-07-29
MY154547A (en) 2015-06-30
PL2094658T3 (pl) 2012-05-31
CA2670340C (en) 2014-05-20
MX2009005251A (es) 2009-08-19
CN101541749B (zh) 2013-03-27
WO2008063867A3 (en) 2008-07-31
BRPI0719092A2 (pt) 2013-12-03

Similar Documents

Publication Publication Date Title
EA200970500A1 (ru) СОЕДИНЕНИЯ ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛА В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРА АНДРОГЕНОВ
EA201071317A1 (ru) ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛЬНЫЕ МОДУЛЯТОРЫ РЕЦЕПТОРОВ АНДРОГЕНОВ
ATE457979T1 (de) Als androgen-rezeptor-modulatoren verwendbare tetrahydrocarbazol-derivate
CY1108690T1 (el) Υποκατεστημενες ν-αρυλοπυρρολιδινες ως επιλεκτικοι διαμορφωτες υποδοχεα ανδρογονων
EA200802007A1 (ru) Соединения, потенцирующие рецептор амра, и применение указанных соединений в медицине
EA201692167A1 (ru) Модуляторы толл-подобных рецепторов
WO2007087548A3 (en) Chemical compounds
ATE430744T1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
PL1735278T3 (pl) Związki receptora histaminowego H3, wytwarzanie i zastosowania terapeutyczne
TW200626158A (en) Naphthaline derivatives
EA201001747A1 (ru) Бензоксазиноновые производные, действующие в качестве агониста бета-2-адренорецептора, для лечения респираторных расстройств
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
WO2008004100A9 (en) Therapeutic compounds
IL206611A0 (en) Novel imidazolinylmethyl aryl sulfonamides
MX2010007928A (es) Imidazolinilmetil aril sulfonamidas novedosas.
MX2010008019A (es) Nuevas imidazolinilmetil aril sulfonamidas.
DOP2009000117A (es) Compuestos de tetrahidrociclopenta[b]indol como moduladores del receptor de andrógenos
EA201990219A2 (ru) Ингибиторы mek и способы их применения